Management of Bradycardia with Antihypertensive Medications

Medication Management

Alpha-blockers like doxazosin should only be held if there are signs of symptomatic hypotension or hemodynamic instability, as recommended by the American Heart Association 1
Irbesartan should be held in patients with bradycardia (HR <60 bpm) as ARBs can potentially worsen hypotension in the setting of bradycardia, according to the European Society of Cardiology 2
In patients with heart failure and bradycardia, reducing or stopping RASi (including ARBs like irbesartan) is recommended when heart rate is below 60 bpm, as suggested by the European Society of Cardiology 2
When managing patients with low blood pressure and bradycardia, guidelines suggest reducing ARBs before other medications if the heart rate is below 60 bpm, as recommended by the European Society of Cardiology 2

Assess for signs of symptomatic bradycardia, including altered mental status, ischemic chest discomfort, acute heart failure, or hypotension, as recommended by the American Heart Association 3
If symptomatic, hold all three medications and consider atropine or temporary pacing, as suggested by the American Heart Association 3
If asymptomatic bradycardia (HR <60 bpm), continue doxazosin unless there is hypotension, as recommended by the American Heart Association 1
Hold irbesartan and nifedipine in patients with asymptomatic bradycardia (HR <60 bpm), as recommended by the European Society of Cardiology 2

Beta-blockers should be titrated to a resting heart rate of 60-65 bpm, but this target does not apply to other antihypertensive classes in the setting of bradycardia, as recommended by the American Heart Association 4
Avoid combining calcium channel blockers with beta-blockers in patients with bradycardia due to potential for worsening conduction abnormalities, as suggested by the American College of Cardiology 5
In patients with heart failure, bradycardia management requires special attention as it may indicate worsening cardiac function or medication side effects, as recommended by the American Heart Association 1, 6

Continuous cardiac monitoring is essential when managing antihypertensives in patients with bradycardia, as recommended by the American Heart Association 3
Monitor for signs of hypoperfusion including altered mental status, dizziness, or worsening symptoms, as suggested by the American Heart Association 6